Ravi K Amaravadi, MD
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member, Abramson Cancer Center
Member, Institute of Translational Medicine and Therapeutics
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
co-Leader , Cancer Therapeutics Program, Abramson Cancer Center
Co-Director, University of Pennsylvania/Wistar Institute SPORE in Skin Cancer
Associate Director, Translational Research, Abramson Cancer Center
Department: Medicine
Graduate Group Affiliations
Contact information
Division of Hematology Oncology
8 BRB - Room 852
Philadelphia, PA 19104
8 BRB - Room 852
Philadelphia, PA 19104
Office: 215-769-5159
Publications
Education:
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent linkBA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Description of Research Expertise
Autophagy, Mechanisms of Cell Death, Developmental TherapeuticsDescription of Clinical Expertise
Phase I and Phase II Clinical TrialsMelanoma
Selected Publications
Jain V, Singh MP, Amaravadi RK.: Recent advances in targeting autophagy in cancer. Trends Pharmacol Sci Mar 2023.Bhardwaj M, Lee JJ, Versace AM, Harper SL, Goldman AR, Crissey MAS, Jain V, Singh MP, Vernon M, Aplin AE, Lee S, Morita M, Winkler JD, Liu Q, Speicher DW, Amaravadi RK.: Lysosomal lipid peroxidation regulates tumor immunity. J Clin Invest Feb 2023.
Jain V, Harper SL, Versace AM, Fingerman D, Brown GS, Bhardwaj M, Crissey MAS, Goldman AR, Ruthel G, Liu Q, Zivkovic A, Stark H, Herlyn M, Gimotty PA, Speicher DW, Amaravadi RK.: Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. Cancer Discov 13: 454-473, Feb 2023.
Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, Speicher DW, Zhang Q, Donthireddy LR, Mostafa A, Tsyganova S, Pisarev V, Laufer T, Ignatov D, Ferrone S, Meyer C, Maby-El Hajjami H, Speiser DE, Altiok S, Antonia S, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Yuan Z, Montaner LJ, Celis E, Gabrilovich DI.: Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell 40: 1173-1189, Oct 2022.
Guan L, Wu B, Li T, Beer LA, Sharma G, Li M, Lee CN, Liu S, Yang C, Huang L, Frederick DT, Boland GM, Shao G, Svitkina TM, Cai KQ, Chen F, Dong MQ, Mills GB, Schuchter LM, Karakousis GC, Mitchell TC, Flaherty KT, Speicher DW, Chen YH, Herlyn M, Amaravadi RK, Xu X, Guo W.: HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8(+) T-cell infiltration into tumors. Nat Commun 13: 4078, Jul 2022.
Anstadt EJ, Chu B, Yegya-Raman N, Han X, Doucette A, Poirier K, Mohiuddin JJ, Maity A, Facciabene A, Amaravadi RK, Karakousis GC, Cohen JV, Mitchell TC, Schuchter LM, Lukens JN.: Moderate Colitis Not Requiring IV Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist Jun 2022.
Karasic TB, Brown TJ, Schneider C, Teitelbaum UR, Reiss KA, Mitchell TC, Massa RC, O'Hara MH, DiCicco L, Garcia-Marcano L, Amaravadi RK, O'Dwyer PJ.: Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. Oncologist May 2022.
Giles JR, Manne S, Freilich E, Oldridge DA, Baxter AE, George S, Chen Z, Huang H, Chilukuri L, Carberry M, Giles L, Weng NP, Young RM, June CH, Schuchter LM, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Huang AC, Shi J, Wherry EJ.: Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Immunity 55: 557-574, Mar 2022.
Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Herlyn M, Dong H, Gimotty PA, Daaboul G, Xu X, Guo W.: ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Dev Cell Jan 2022.
Mehnert JM, Mitchell T, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis G, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi R.: BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma. Clin Cancer Res Jan 2022.